文献速递胸部肿瘤放疗

大块不可切除Ⅲ期非小细胞肺癌患者在接受根治性放化疗前诱导免疫检查点抑制剂联合化疗

Induction Immune Checkpoint Inhibitors and Chemotherapy Before Definitive Chemoradiation Therapy for Patients With Bulky Unresectable Stage III Non-Small Cell Lung Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2023-01-07

本研究纳入2018至2022年接受诱导免疫检查点抑制剂联合化疗后行根治性放化疗的75例大块不可切除Ⅲ期非小细胞肺癌患者,分析生存与毒性,并模拟诱导前后放疗计划剂量学变化。2周期诱导方案可行,肿瘤显著缩小且正常肺受量降低,但需进一步研究放化疗联合诱导及巩固免疫治疗。

要点

  • 75例大块不可切除Ⅲ期非小细胞肺癌患者接受诱导免疫检查点抑制剂联合化疗后行根治性放化疗。
  • 1年和2年总生存率分别为91.5%和75.1%,1年和2年无进展生存率分别为85.8%和64.2%。
  • ≥3级肺炎发生率为9.3%,且与更差的总生存和无进展生存显著相关。

核心结论

  • 根治性放化疗前2周期诱导免疫检查点抑制剂联合化疗对大块局部晚期非小细胞肺癌可行,肿瘤显著缩小并保护正常肺组织。
  • 作者认为需进一步研究放化疗联合诱导及巩固免疫检查点抑制剂治疗。

研究设计与样本

  • 研究纳入2018年至2022年接受免疫检查点抑制剂联合化疗后行根治性放化疗的大块不可切除Ⅲ期非小细胞肺癌患者75例。
  • 大块定义为原发肿瘤最大径≥5 cm或转移淋巴结最短径≥2 cm。
  • 分析生存结局与毒性效应,并基于2周期诱导化疗免疫治疗前后的计算机断层扫描图像模拟放疗计划以评估剂量学结局。

主要发现

  • 1年和2年总生存率分别为91.5%(95% CI,85.2%-98.3%)和75.1%(95% CI,64.1%-88.0%)。
  • 1年和2年无进展生存率分别为85.8%(95% CI,78.0%-94.4%)和64.2%(95% CI,52.5%-78.6%)。
  • 中位总生存未达到,中位无进展生存为30.6个月(95% CI,25.9个月至未达到)。
  • 2级和≥3级肺炎分别发生于26.7%和9.3%的患者,≥3级肺炎与更差的总生存(P = .003)和无进展生存(P = .018)显著相关。
  • 治疗中断与更短的总生存(P = .023)和无进展生存(P = .047)显著相关;接受巩固免疫检查点抑制剂的患者总生存数值上优于未接受者(2年总生存率,85.8% vs 64.2%;P = .170)。

临床怎么用

  • 原文结论认为根治性放化疗前2周期诱导免疫检查点抑制剂联合化疗对大块局部晚期非小细胞肺癌可行。
  • 作者认为需进一步研究放化疗联合诱导及巩固免疫检查点抑制剂治疗。

局限性

  • 原文结论指出需进一步研究放化疗联合诱导及巩固免疫检查点抑制剂治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In the era of immunotherapy, the treatment for bulky, locally advanced non-small cell lung cancer (LA-NSCLC) remains challenging. This study explored the feasibility of induction immune checkpoint inhibitors (ICIs) plus chemotherapy before definitive chemoradiation therapy (CRT) for bulky LA-NSCLC. METHODS AND MATERIALS: Patients with bulky, unresectable stage III NSCLC (primary tumor ≥5 cm in greatest dimension or metastatic lymph nodes ≥2 cm in shortest diameter) receiving ICIs and chemotherapy before CRT from 2018 to 2022 were identified. Survival outcomes and toxic effects were analyzed. Radiation therapy plans on computed tomography images before and after 2 cycles of induction chemoimmunotherapy were simulated to evaluate dosimetric outcomes. RESULTS: Seventy-five patients were included. One- and 2-year overall-survival (OS) rates were 91.5% (95% CI, 85.2%-98.3%) and 75.1% (95% CI, 64.1%-88.0%), respectively. One- and 2-year progression-free-survival (PFS) rates were 85.8% (95% CI, 78.0%-94.4%) and 64.2% (95% CI, 52.5%-78.6%), respectively. Median OS was not reached (NR). Median PFS was 30.6 months (95% CI, 25.9 months to NR). Grade 2 and ≥3 pneumonitis occurred in 26.7% and 9.3% of patients, respectively. Grade ≥3 pneumonitis was significantly associated with poorer OS (P = .003) and PFS (P = .018). Treatment discontinuation was significantly associated with shorter OS (P = .023) and PFS (P = .047). Patients with consolidation ICIs exhibited numerically better OS than those without consolidation ICIs (2-year OS, 85.8% vs 64.2%; P = .170). The objective response rate was 76.1% for induction treatment and 86.7% for induction treatment plus CRT. The disease control rate after 2 cycles of induction therapy was significantly greater than after 4 (P = .046) or more cycles (P = .025). Simulated radiation plans indicated that all target volumes, mean lung dose, and volume of lung parenchyma receiving ≥5 Gy, ≥20 Gy, and ≥30 Gy significantly decreased after 2 cycles (all P < .005). CONCLUSIONS: Two cycles of induction ICIs plus chemotherapy before definitive CRT were feasible for bulky LA-NSCLC, with significant tumor reduction and normal lung protection. Further investigations on CRT combined with induction and consolidation ICIs are warranted.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Wang Y, Zhang T, Wang J, et al. Induction Immune Checkpoint Inhibitors and Chemotherapy Before Definitive Chemoradiation Therapy for Patients With Bulky Unresectable Stage III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2023. PMID: 36623605. doi:10.1016/j.ijrobp.2022.12.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。